315 related articles for article (PubMed ID: 25273092)
1. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.
Kalra AV; Kim J; Klinz SG; Paz N; Cain J; Drummond DC; Nielsen UB; Fitzgerald JB
Cancer Res; 2014 Dec; 74(23):7003-13. PubMed ID: 25273092
[TBL] [Abstract][Full Text] [Related]
2. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
3. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.
Kang MH; Wang J; Makena MR; Lee JS; Paz N; Hall CP; Song MM; Calderon RI; Cruz RE; Hindle A; Ko W; Fitzgerald JB; Drummond DC; Triche TJ; Reynolds CP
Clin Cancer Res; 2015 Mar; 21(5):1139-50. PubMed ID: 25733708
[TBL] [Abstract][Full Text] [Related]
4. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
6. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
7. Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization.
Rose WC; Marathe PH; Jang GR; Monticello TM; Balasubramanian BN; Long B; Fairchild CR; Wall ME; Wani MC
Cancer Chemother Pharmacol; 2006 Jul; 58(1):73-85. PubMed ID: 16228206
[TBL] [Abstract][Full Text] [Related]
8. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB
Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454
[TBL] [Abstract][Full Text] [Related]
9. Antimyeloma activity of NK012, a micelle-forming macromolecular prodrug of SN-38, in an orthotopic model.
Miyazaki O; Sekine K; Nakajima N; Ichimura E; Ebara K; Nagai D; Onda T; Miyakawa Y; Okamoto K; Morino T
Int J Cancer; 2014 Jan; 134(1):218-23. PubMed ID: 23775066
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
11. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.
Lei S; Chien PY; Sheikh S; Zhang A; Ali S; Ahmad I
Anticancer Drugs; 2004 Sep; 15(8):773-8. PubMed ID: 15494639
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel 10-substituted-7-ethyl-10-hydroxycamptothecin (SN-38) prodrugs.
Zhou M; Liu M; He X; Yu H; Wu D; Yao Y; Fan S; Zhang P; Shi W; Zhong B
Molecules; 2014 Nov; 19(12):19718-31. PubMed ID: 25438082
[TBL] [Abstract][Full Text] [Related]
13. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors.
Koizumi F; Kitagawa M; Negishi T; Onda T; Matsumoto S; Hamaguchi T; Matsumura Y
Cancer Res; 2006 Oct; 66(20):10048-56. PubMed ID: 17047068
[TBL] [Abstract][Full Text] [Related]
14. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.
Fang T; Dong Y; Zhang X; Xie K; Lin L; Wang H
Int J Pharm; 2016 Oct; 512(1):39-48. PubMed ID: 27544846
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.
Noble CO; Krauze MT; Drummond DC; Forsayeth J; Hayes ME; Beyer J; Hadaczek P; Berger MS; Kirpotin DB; Bankiewicz KS; Park JW
Nanomedicine (Lond); 2014 Jul; 9(14):2099-108. PubMed ID: 24494810
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models.
Matsuzaki T; Takagi A; Furuta T; Ueno S; Kurita A; Nohara G; Kodaira H; Sawada S; Hashimoto S
Oncol Rep; 2012 Jan; 27(1):189-97. PubMed ID: 21935577
[TBL] [Abstract][Full Text] [Related]
17. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
Zamboni WC; Houghton PJ; Thompson J; Cheshire PJ; Hanna SK; Richmond LB; Lou X; Stewart CF
Clin Cancer Res; 1998 Feb; 4(2):455-62. PubMed ID: 9516936
[TBL] [Abstract][Full Text] [Related]
18. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan.
Ko AH
Int J Nanomedicine; 2016; 11():1225-35. PubMed ID: 27099488
[TBL] [Abstract][Full Text] [Related]
19. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
Chen PY; Ozawa T; Drummond DC; Kalra A; Fitzgerald JB; Kirpotin DB; Wei KC; Butowski N; Prados MD; Berger MS; Forsayeth JR; Bankiewicz K; James CD
Neuro Oncol; 2013 Feb; 15(2):189-97. PubMed ID: 23262509
[TBL] [Abstract][Full Text] [Related]
20. Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
Oosterhoff D; Pinedo HM; van der Meulen IH; de Graaf M; Sone T; Kruyt FA; van Beusechem VW; Haisma HJ; Gerritsen WR
Br J Cancer; 2002 Sep; 87(6):659-64. PubMed ID: 12237777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
